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Allosteric activation of antithrombin as a rapid inhibitor of factors IXa and Xa requires binding of a
high-afﬁnity heparin pentasaccharide. The currently-accepted mechanism involves removal of a
constraint on the antithrombin reactive center loop (RCL) so that the proteinase can simultaneously
engage both the P1 arginine and an exosite at Y253. Recent results suggest that this mechanism is
incorrect in that activation can be achieved without loop expulsion, while the exosite can be
engaged in both low and high activity states. We propose a quite different mechanism in which hep-
arin activates antithrombin by mitigating an unfavorable surface interaction, by altering its nature,
and by moving the attached proteinase away from the site of the unfavorable interaction through
RCL expulsion.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Antithrombin is the principal serpin inhibitor and regulator of
the blood coagulation proteinases thrombin, factor Xa and factor
IXa [1]. However, in the absence of heparin the second order rate
constants for inhibition (k2) of each proteinase are too low to be
physiologically effective, with values of 28  103 M1 s1 for fac-
tor Xa and thrombin [2] and only 2  102 M1 s1 for factor IXa [1].
Heparin dramatically enhances rates by two distinct mechanisms.
First, a high-afﬁnity heparin pentasaccharide (H5) binds anti-
thrombin and causes allosteric changes that result in 100 to 300-
fold increases in k2 for factors IXa and Xa, respectively, but less
than 1-fold increase for thrombin [2]. Longer heparins can simulta-
neously bind both antithrombin and each proteinase [3]. This
bridging produces rate enhancements of 1000-fold for thrombin,
100-fold for factor IXa and 10-fold for factor Xa.
A fundamental question is how allosteric activation of antiti-
thrombin occurs. With the suggestion from X-ray structures of
heparin-free [4,5] and heparin-bound antithrombin [6] that hepa-
rin binding might allow greater movement of the reactive centerchemical Societies. Published by E
charide; RCL, reactive center
ttins), stolson@uic.edu (S.T.loop (RCL), through expulsion of the latter’s constrained N-termi-
nal end, as well as the structure of antithrombin in ternary com-
plex with activating H5 and factor Xa (S195A), in which factor Xa
engages both P1 Arg and an exosite containing Y253 [7], it seemed
that the answer had been found. Thus, the current, widely accepted
mechanism of antithrombin activation is that, with the RCL hinge
buried at the top of b-sheet A in the native state, the RCL is con-
strained such that factor Xa or IXa can bind only to P1 Arg and
adjacent residues, but not to the Y253 exosite (Fig. 1A). This inabil-
ity to engage the exosite is proposed to explain the low rate of
reaction by these two rather inefﬁcient proteinases. H5 binding ex-
pels the buried RCL hinge, giving it sufﬁcient extra unconstrained
length to permit either proteinase to simultaneously engage both
P1 and the exosite. The extra favorable interaction with the exosite
is thus the source of the rate enhancement. In this model a low, but
otherwise normal rate of reaction between antithrombin and pro-
teinase, is changed to one in which enhancement arises through
additional favorable interactions.
2. Problems with the current mechanism
The most pressing reason to re-evaluate this model was a study
just conducted in our laboratories on an antithrombin variant in
which residues 131–136 were mutated to a-helix-promoting ones
(YRKANK changed to LEEAAE) [8]. This variant had a basal rate of
factor Xa inhibition (k2  3.1  105 M1 s1)  50-fold higher thanlsevier B.V. All rights reserved.
Fig. 1. Old and new mechanisms of heparin activation of antithrombin as an
inhibitor of factors IXa and Xa. Panel A, current, old mechanism of activation in
which proteinase (blue) only engages P1 Arg (green elipse) in the unactivated state
(AT) to give one favorable (+) interaction. H5 (green balls) binding causes
conformational changes (black arrow) that result in RCL hinge expulsion, upward
and horizontal movement of the proteinase so that it can engage both P1 Arg and
Y253, to give two favorable (+,+) interactions. Binding energy differences between
serpin and proteinase in the activated vs. unactivated states arise from additional
engagement of Y253 in the latter. Panel B, newmechanism of activation. In the non-
activated state (AT) the proteinase engages both P1 Arg and Y253, but these two
favorable interactions (+,+) are partly offset by the repulsion () between patches
(dark blue) on the proteinase and the serpin. H5 binding causes conformation
changes that expel the RCL hinge, but also alter the repulsive region on
antithrombin (lighter shade of blue) so that the interaction with the repulsive
patch on the proteinase is diminished (interaction reduced from ‘‘” to ‘‘d”). The
energy difference for binding of serpin and proteinase in activated vs. unactivated
states arises from (i) reduction in the unfavorable interaction from ‘‘” to ‘‘d”, and
(ii) movement away of the proteinase from the repulsive patch on antithrombin.
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being inserted into b-sheet A. These included near-normal Trp ﬂuo-
rescence that was enhanced 25% upon binding H5 and only mod-
estly enhanced heparin afﬁnity (2 decrease in Kd). A further 6-
fold rate enhancement, together with RCL expulsion, occurred
when H5 bound, to give 3-fold higher k2 than wild-type anti-
thrombin bound to H5. Signiﬁcantly, an earlier study in which only
Y131 was changed to Ala or Leu found a similar effect, with greatly
enhanced basal rate of factor Xa inhibition in the absence of hepa-
rin (25 to 29-fold) and a further 8 to 12-fold enhancement when
H5 bound [9]. Since in both cases most of the activation occurred
while the RCL hinge was still constrained by b-sheet A, this raised
doubts about the role of RCL hinge expulsion as the means of acti-
vation through engagement of a new favorable exosite.
Concerning the accessibility and role of the proposed exosite,
Y253, in native and heparin-activated states, two quite different
published datasets suggest that, while Y253 is indeed engaged by
factor Xa and factor IXa, this occurs in both native and heparin-
bound states, rather than the exosite being available only in the
heparin-activated state. In one study Y253 was mutated and the ef-
fects on basal and heparin-activated rates of inhibition of throm-
bin, factor IXa and factor Xa examined [10]. Replacement with
Ala had minimal effect on the basal rate of thrombin inhibition,but reduced the rate of factor IXa inhibition by 200-fold and of
factor Xa by 10-fold. This suggests that Y253 already binds factor
IXa and factor Xa in the low activity, loop-inserted state, and must
make a major contribution to the interaction. Strikingly the Y253A
variant still showed the normal 200-fold rate enhancement upon
H5 binding for both factor IXa and factor Xa, even though Y253
was absent. The second type of data to suggest that Y253 is en-
gaged in both heparin-free and heparin-bound states is more cir-
cumstantial. In the currently-accepted mechanism, it is suggested
that loop expulsion is needed to remove constraints on the RCL
so that either factor Xa or factor IXa can simultaneously engage
P1 Arg and Y253. This implies that these two groups are too far
apart in the native state to permit this. X-ray structures suggest
that this is incorrect. The ﬁrst structures of native antithrombin
showed Ca–Ca separation between P1 Arg and Y253 of 16 Å [4,5].
A more recent structure had Ca–Ca of a mere 10 Å between P1
and Y253 [11]. These structures demonstrate that the RCL is sufﬁ-
ciently ﬂexible in the loop-inserted state for the position of the P1
Ca to move by 6 Å, as dictated by circumstances. In three structures
of antithrombin in heparin-bound non-covalent Michaelis complex
with proteinase the separation between P1 and Y253 Ca is 17–19 Å
in the two thrombin complexes [3,12] and 19 Å in the factor Xa
complex [7]. This negates the idea that loop expulsion is needed
to provide extra length to the RCL and thereby allow the P1 Arg
to move closer to Y253 and so permit factor Xa or factor IXa to en-
gage both residues, since the separation is larger than in the native
state. P1 and Y253 are already almost exactly the correct distance
apart in the native loop-inserted state. Together with the mutagen-
esis data indicating that Y253 is important for binding factor IXa or
factor Xa in the native state, this supports the idea that, while both
Y253 and P1 are bound by the proteinase in both native and acti-
vated states, Y253 cannot be the source of the activating rate
enhancements for either factor IXa or factor Xa.3. Hypothesis
We propose a quite different mechanism of allosteric activation
of antithrombin against factors IXa and Xa that still recognizes the
importance of expulsion of the RCL hinge, but only as the minor of
two factors that together produce the overall rate enhancement
(Fig. 1B). In our new model both P1 Arg and Y253 in native anti-
thrombin can be simultaneously engaged by factors IXa and Xa,
and both contribute favorably to the binding interaction (‘‘+” in
Fig. 1B). The overall afﬁnity, and consequently the on-rate that
determines k2 for Michaelis complex formation, remains low how-
ever, because of additional unfavorable interaction(s) between the
proteinase and the surface of the antithrombin (‘‘” in Fig. 1B). If
the Y253 exosite were not available in the native state, the binding
to P1 Arg, and hence rate of inhibition, would be even lower than is
observed. When H5 binds, two distinct changes occur with respect
to activation. One is a change on the antithrombin surface, medi-
ated in some way by Y131, that results in decreased unfavorable-
ness of the negative proteinase–antithrombin interaction (from
‘‘” to ‘‘d” in AT*, Fig. 1B). The second is expulsion of the RCL
hinge that allows the N-terminal end to move out from the anti-
thrombin surface and hence reduces the repulsive proteinase–anti-
thrombin interaction due to increase in separation. This implies
that the repulsive site should lie on the antithrombin surface close
to the N-terminal end of the RCL. As with complexes formed with
native antithrombin, both P1 Arg and Y253 are engaged in the hep-
arin-activated state. The major energetic, and hence kinetic, differ-
ence in formation of the antithrombin–proteinase complex when
heparin is bound is that favorable binding contributions from P1
and Y253 are no longer diminished by unfavorable interaction with
the antithrombin surface. Since the reduction in the unfavorable
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separation from the repulsive site, each of these should contribute
additively in terms of binding energy and could, in appropriate
antithrombin variants, occur as separate events, such as in our re-
cent study [8]. From that study an estimate of the relative changes
arising from change in the repulsive epitope and movement of the
RCL can be made of 50-fold and 6-fold, respectively, though these
exact values need not necessarily apply in wild-type antithrombin,
where both processes would occur together when heparin binds
and where there are, by deﬁnition, no mutations that might alter
the nature of the surface alterations.4. Where is the unfavorable interaction site?
It is not possible at present to unambiguously identify residues
on either antithrombin or factors IXa or Xa that interact unfavor-
ably to down-regulate the inhibition rate. However, in studies to
identify the putative proteinase exosite on antithrombin, six swaps
of b-strands or loops from regions on antithrombin close to the RCL
were made between a1PI and antithrombin [13], of which only that
of s3c, which contains Y253, resulted in loss of activation upon
heparin binding. This gave only a 2-fold rate enhancement for fac-
tor Xa inhibition and a reduction of about 40% for factor IXa inhibi-
tion when H5 bound [13]. In addition, the basal rate of factor IXa
inhibition was reduced only 2-fold and that of factor Xa by 20%,
despite the absence of Tyr at position 253 and its replacement by
Lys. Together, these observations are consistent with the b-strand
swap simultaneously removing the unfavorable interaction and
the favorable Y253 interaction. Removal of the unfavorable interac-
tion at the same time as loss of the favorable Y253 exosite offset
one another to give only a slightly altered basal rate, whereas the
removal of the unfavorable interaction eliminated any rate
enhancement possible from heparin-induced conformational
changes. Of residues close enough to the RCL to be possible sources
of difference in behavior in the strand-swap variant, 254QEgK,
which were changed to 254RLgM, are likely candidates. Both
Q254 and E255 are conserved in the 13 sequenced antithrombins,
while K257 is either K or R in 12 [14]. Signiﬁcantly, these residues
lie directly beneath the middle of the RCL and so fulﬁll the expec-
tation that the repulsive site should be close to where factor Xa
would dock with the RCL in the unactivated state.5. Re-evaluation of other relevant data
Besides our recent data on the 131–136 antithrombin variant,
other studies have proved difﬁcult to interpret on the old model,
but are more readily explained using our new mechanism. One in-
volved stepwise deletions of antithrombin residues 134–137 [15].
Removal of 134–137 produced a 2-fold reduction in basal rate of
factor Xa inhibition, but still left a 44-fold enhancement upon hep-
arin binding, despite only 9% ﬂuorescence enhancement. The latter
was interpreted as representing a shift in equilibrium between
inactive loop-inserted and active loop-expelled states of only
25% (i.e. giving 1/4th of the expected 40% ﬂuorescence enhance-
ment). However, even there it was recognized that the magnitude
of the ﬂuorescence change represented a discrepancy between
what might be expected on this simple shift in equilibrium and
what was found. This was exacerbated when it was shown that
about 1/5th of the normal ﬂuorescence enhancement (i.e. about
8%) arose from W49 and W189 and probably did not reﬂect loop
expulsion per se [16]. Using our new model, those data can be sim-
ply interpreted as the deletions resulting in an inability to expel
the RCL hinge upon heparin binding and hence giving only 9% ﬂuo-
rescence enhancement. Without loop expulsion, the observedenhancement in factor Xa inhibition rate would arise from sur-
face-mediated reduction in the unfavorable antithrombin–factor
Xa interaction. Strikingly, the observed 44-fold enhancement is
very close to the 50-fold enhancement seen for the 131–136 vari-
ant in the absence of heparin [8].
Similar behavior was observed for K133P antithrombin [17]. As
with the deletion mutants, heparin binding produced only a small
ﬂuorescence enhancement (10%) but still gave 40-fold enhanced
rate of factor Xa inhibition. The new interpretation is that heparin-
induced loop expulsion has been blocked by the introduction of Pro
and so the only heparin-induced changes that contribute to activa-
tion are surface-mediated ones that reduce the repulsive factor Xa–
antithrombin interaction.
A third study was on a P14C antithrombin variant in which Cys
was derivatized with ﬂuorescein [18]. Here, Cys could only be efﬁ-
ciently derivatized in the heparin-bound state, indicating that RCL
hinge expulsion was needed to expose the SH group. It was as-
sumed that the bulky ﬂuorescein would prevent the P14 backbone
from re-inserting into b-sheet A upon heparin removal. The 200-
fold rate enhancement of the derivative with factor Xa was consis-
tent with this and hence with the sufﬁciency of loop expulsion to
give full activation. However, a subsequent X-ray structure of the
derivative showed that the RCL hinge was still inserted into b-
sheet A and the ﬂuorescein moiety lay on the antithrombin surface
close to the RCL N-terminus [19]. The derivative also had normal
Trp ﬂuorescence, which was enhanced 38% upon heparin binding,
again implying that the RCL hinge is inserted into b-sheet A and
is subsequently expelled upon heparin binding (Gettins, P.G.W.
and Huntington, J.A., unpublished results). If this interpretation is
correct, the highly activated state in the absence of heparin cannot
arise from expulsion of the RCL hinge, but instead from some sur-
face change induced by the negatively charged ﬂuorescein.
An antithrombin variant whose behavior could be interpreted
by either model is P14E(S380E) [20] (and unpublished data, Roth
and Olson). Its ﬂuorescence (40% enhanced intensity compared
with wild-type antithrombin, but no change upon binding heparin)
indicates that its RCL is fully expelled and its rate of reaction with
factor Xa already represents full activation, even in the absence of
heparin. Seemingly this correlated with Glu inducing loop expul-
sion and consequently producing the rate enhancement. However,
a P14R variant has Trp ﬂuorescence similar to loop-inserted wild-
type antithrombin, gives 20% enhancement upon heparin binding
and yet already reacts 50-fold faster with factor Xa (Ryan Roth
and Steven Olson, unpublished results). Our model suggests an
alternative interpretation in which the charge at P14, whether po-
sitive (Arg) or negative (Glu), results in amelioration of the repul-
sive factor Xa–antithrombin interaction, and that whether the
RCL hinge is expelled or not results in only small additional
changes.6. Summary
Published data on the role of Y253 of antithrombin in the inhi-
bition of factors IXa and Xa demonstrate that, although Y253 is a
critical exosite, it is used in both native and heparin-activated
states and so cannot be the source of heparin-induced rate
enhancements. To-be-published data on a helix-D variant of anti-
thrombin further show that RCL hinge expulsion is not required
to give very large activation of antithrombin as a factor Xa inhibitor
[8]. These observations are inconsistent with the current mecha-
nism of heparin activation, which involves heparin-induced con-
formational change to expel the RCL hinge and hence permit
engagement of the Y253 exosite. Our new model proposes that
Y253 is engaged in both native and activated states and so does
not contribute to H5-induced rate enhancement. Instead,
3400 P.G.W. Gettins, S.T. Olson / FEBS Letters 583 (2009) 3397–3400heparin-induced conformational changes in antithrombin reduce
or eliminate a repulsive interaction with factor Xa or IXa that
otherwise reduces their rates of reaction with antithrombin, result-
ing in a 30 to 50-fold rate enhancement. Additionally, RCL expul-
sion allows the proteinase to move further away from the
repulsive site, giving a further rate enhancement of 6 to 12-fold.
Other studies on antithrombin variants that were difﬁcult to inter-
pret can now be understood using the new mechanism, lending
further support to its validity.
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